Qiagen (NYSE:QGEN) Receives $55.53 Average PT from Brokerages

Qiagen (NYSE:QGENGet Rating) has been given an average rating of “Hold” by the seven brokerages that are currently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $55.53.

Several brokerages have recently issued reports on QGEN. Citigroup raised their price target on shares of Qiagen from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Thursday, February 9th. Berenberg Bank lifted their price objective on Qiagen from €53.91 ($57.35) to €54.60 ($58.09) in a research report on Friday, November 11th. Finally, UBS Group raised their target price on Qiagen from $50.00 to $52.00 and gave the company a “neutral” rating in a research note on Thursday, February 9th.

Qiagen Price Performance

NYSE:QGEN opened at $46.00 on Monday. The firm has a market capitalization of $10.45 billion, a price-to-earnings ratio of 25.01, a P/E/G ratio of 1.26 and a beta of 0.40. The stock’s 50 day moving average price is $48.87 and its two-hundred day moving average price is $46.62. Qiagen has a 12-month low of $40.38 and a 12-month high of $51.18. The company has a quick ratio of 2.09, a current ratio of 2.46 and a debt-to-equity ratio of 0.42.

Qiagen (NYSE:QGENGet Rating) last posted its quarterly earnings results on Tuesday, February 7th. The company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of $0.47 by $0.06. The company had revenue of $531.00 million for the quarter, compared to the consensus estimate of $486.93 million. Qiagen had a net margin of 19.76% and a return on equity of 16.45%. The firm’s quarterly revenue was down 8.8% compared to the same quarter last year. During the same period last year, the company posted $0.74 EPS. On average, analysts anticipate that Qiagen will post 2.11 earnings per share for the current year.

Institutional Investors Weigh In On Qiagen

Several institutional investors and hedge funds have recently modified their holdings of QGEN. IFP Advisors Inc boosted its stake in Qiagen by 133.0% during the third quarter. IFP Advisors Inc now owns 755 shares of the company’s stock worth $41,000 after buying an additional 431 shares during the period. Daiwa Securities Group Inc. purchased a new position in Qiagen during the third quarter valued at approximately $32,000. CWM LLC increased its position in shares of Qiagen by 314.4% during the third quarter. CWM LLC now owns 866 shares of the company’s stock worth $36,000 after purchasing an additional 657 shares in the last quarter. Wipfli Financial Advisors LLC acquired a new position in shares of Qiagen during the third quarter worth $36,000. Finally, NuWave Investment Management LLC acquired a new position in shares of Qiagen during the third quarter worth $45,000. Institutional investors own 58.62% of the company’s stock.

About Qiagen

(Get Rating)

QIAGEN NV is a provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis.

Read More

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.